MAI Capital Management’s Neurogene NGNE Stock Holding History

MAI Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11	Closed	-$222	–	3763
2026 Q1	$222	Buy	+11	New	+$213	﹤0.01%	4600

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

MAI Capital Management's NGNE Position: Q2 2026 in Review

MAI Capital Management sold out of Neurogene (NGNE) in Q2 2026, closing a stake of 11 shares — an estimated $222 sold.

MAI Capital Management first reported a position in NGNE in Q1 2026 and held it in 1 quarter. The position peaked at $222 in Q1 2026. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

MAI Capital Management reported no remaining Neurogene position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 11 Neurogene shares in Q2 2026, an estimated $222.
MAI Capital Management first reported a position in Neurogene in Q1 2026 and held it in 1 quarter.
MAI Capital Management's Neurogene position peaked at $222 in Q1 2026.
112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.